An open-label, parallel-group study to determine the single and multiple dose pharmacokinetics of LAF237 [vildagliptin] and its metabolites in mild renal impaired patients compared to age, sex and weight-matched healthy volunteers following daily doses of 100 mg LAF237 for 14 days.

Trial Profile

An open-label, parallel-group study to determine the single and multiple dose pharmacokinetics of LAF237 [vildagliptin] and its metabolites in mild renal impaired patients compared to age, sex and weight-matched healthy volunteers following daily doses of 100 mg LAF237 for 14 days.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 May 2012

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Renal impairment
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 01 May 2012 Actual patient number is 29 according to ClinicalTrials.gov.
    • 01 May 2012 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
    • 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top